Calls
25
#1231
Alpha Score 32.6
Paul Gabrail
Host / Value Investor
Win Rate
56.0%
return
+0.8%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 26
$54.43
+15.7%
Paul sees Bristol Myers Squibb as an interesting opportunity: it trades at about 7.5x free cash flow and 19x earnings, free cash flow is far above net income, the 4.4% dividend is easily covered, and while Eliquis and Opdivo are losing patent protection, the company plans 16 new products by 2030 targeting over $25 billion in revenue plus cost cuts. His 10-year model values it between $70 and $145, with a $103 midpoint, versus a current price around $55, though he warns the path will be volatile.
Pharma & Biotech
Long
Jan 26
$44.89
+16.6%
Barron's frames SL Green as a contrarian recovery play on Manhattan's office market, and Paul says he loves the commercial landlord play because he always thought the office exodus was a short-term blip: in-person camaraderie matters, office usage is rebounding, and the stock was priced for that recovery, though he acknowledges it still feels scary.
REITs
Long
Jan 24
$479.17
+6.3%
Paul endorses Monish Pabrai's core strategy of regularly investing in the S&P 500 (or, as an acceptable alternative, Berkshire Hathaway) rather than sitting in cash and trying to time a crash. Staying consistently invested captures long-term growth of diversified businesses, compounding, and the tendency of the S&P 500 to recover to new highs after major declines. Paul personally prefers the S&P 500 over Berkshire.
Capital Markets
Showing 3 of 25 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Paul Gabrail has 25 trade ideas tracked on Buzzberg across 25 tickers since January 2026. Win rate 56% across 25 evaluated calls, average return +0.8%. Ranked #1231 on the Buzzberg Alpha leaderboard. Most covered: SPY, SFM, ADBE.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
